This company is no longer active
Eiger BioPharmaceuticals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Eiger BioPharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 27.2% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 01
The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%
Jan 04Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%
Dec 20Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher
Nov 09Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt
Oct 06Eiger sheds ~20% on abandonment of EUA request for COVID therapy
Oct 05Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy
Sep 06Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst
Jul 26European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy
Jul 20In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eiger BioPharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 16 | -75 | -75 | -75 | N/A |
| 9/30/2023 | 15 | -87 | -83 | -83 | N/A |
| 6/30/2023 | 15 | -96 | -89 | -89 | N/A |
| 3/31/2023 | 15 | -97 | -89 | -89 | N/A |
| 12/31/2022 | 13 | -97 | -83 | -83 | N/A |
| 9/30/2022 | 14 | -93 | -78 | -78 | N/A |
| 6/30/2022 | 13 | -89 | -76 | -76 | N/A |
| 3/31/2022 | 11 | -86 | -75 | -75 | N/A |
| 12/31/2021 | 12 | -34 | -71 | -71 | N/A |
| 9/30/2021 | 9 | -31 | -70 | -70 | N/A |
| 6/30/2021 | 6 | -24 | -65 | -65 | N/A |
| 3/31/2021 | 4 | -21 | -60 | -60 | N/A |
| 12/31/2020 | N/A | -65 | -63 | -63 | N/A |
| 9/30/2020 | N/A | -63 | -63 | -63 | N/A |
| 6/30/2020 | N/A | -66 | -64 | -63 | N/A |
| 3/31/2020 | N/A | -68 | -63 | -62 | N/A |
| 12/31/2019 | N/A | -70 | -64 | -64 | N/A |
| 9/30/2019 | N/A | -70 | -61 | -61 | N/A |
| 6/30/2019 | N/A | -68 | -60 | -60 | N/A |
| 3/31/2019 | N/A | -61 | -53 | -53 | N/A |
| 12/31/2018 | N/A | -52 | -43 | -43 | N/A |
| 9/30/2018 | N/A | -47 | -41 | -41 | N/A |
| 6/30/2018 | N/A | -39 | -35 | -35 | N/A |
| 3/31/2018 | N/A | -40 | -36 | -36 | N/A |
| 12/31/2017 | N/A | -42 | -38 | -38 | N/A |
| 9/30/2017 | N/A | -44 | N/A | -39 | N/A |
| 6/30/2017 | N/A | -47 | N/A | -38 | N/A |
| 3/31/2017 | N/A | -49 | N/A | -45 | N/A |
| 12/31/2016 | N/A | -47 | N/A | -38 | N/A |
| 9/30/2016 | N/A | -41 | N/A | -30 | N/A |
| 6/30/2016 | N/A | -33 | N/A | -25 | N/A |
| 3/31/2016 | N/A | -22 | N/A | -12 | N/A |
| 12/31/2015 | N/A | -13 | N/A | -9 | N/A |
| 9/30/2015 | N/A | -7 | N/A | -6 | N/A |
| 12/31/2014 | N/A | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if EIGR.Q's forecast earnings growth is above the savings rate (2.5%).
Earnings vs Market: Insufficient data to determine if EIGR.Q's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if EIGR.Q's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if EIGR.Q's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if EIGR.Q's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EIGR.Q's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/02 11:03 |
| End of Day Share Price | 2024/10/01 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eiger BioPharmaceuticals, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Brian Skorney | Baird |
| Madhu Kumar | B. Riley Securities, Inc. |